Medtech
5 Early-Stage Surgical Technology Startups Changing How Procedures Are Performed
DealBio tracks early-stage surgical technology startups across Europe and North America. These 5 are changing how procedures are visualized, guided and executed across reconstructive surgery, nerve repair, ophthalmology, hard-tissue surgery and embolization.
- Surgical Technology
- Medical Devices
- Surgical Robotics
- Medical Imaging
- Interventional Radiology
Surgical innovation is increasingly moving into the procedure itself. Instead of only improving pre-operative planning or introducing a new implant, early-stage teams are building tools that change what clinicians can see, how they navigate anatomy and what options remain available during an intervention.
Across this group, the shared opportunity is workflow-level improvement. The technologies are designed to fit into existing operating-room or catheter-based procedures while adding clearer visualization, more repeatable guidance or a simpler way to perform a technically demanding step.
At a Glance
- ExolumenNetherlands2024Projects patient-specific anatomy onto the operative field
- Atraxon BiotechNetherlands2024Simplifies surgical prevention and treatment of painful neuromas
- OculumCanada2024Adds dye-free virtual staining to retinal surgery
- Surgitec RoboticsFrance2023Uses one robotic platform across hard-tissue procedures
- LaNua MedicalIreland2024Blocks blood flow while preserving downstream catheter access
01
Exolumen
Developing surgical projectors that overlay anatomical data directly onto patients.
- Country
Netherlands- Founded
- 2024
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why Exolumen stands out
Exolumen has clinical evidence behind the projected anatomical overlay, a patient-specific image placed directly onto the body so the surgical team can see mapped structures in the operative field. A randomized trial of the earlier Anatomy Projector reduced flap-harvest time by 19 minutes, while the technology was used in more than 400 surgeries at Radboudumc before Exolumen was incorporated.
A 2025 feasibility study also found that 82.1% of surgically identified vessels were within 3 cm of a projected thermal hotspot, adding another validation route for vessel localization.
What Exolumen is building
Exolumen is developing an AR Projector for image-guided surgery, procedures in which medical images help clinicians localize anatomy and guide actions during an operation. The system projects vessel locations from pre-operative CT scans directly onto the patient and automatically corrects the overlay as the patient or device moves.
A thermal-imaging module captures skin-temperature patterns and projects them onto the patient to support vessel mapping. The shared, headset-free view is designed to keep the surgical team focused on the operative field rather than a separate screen.
Developing surgical devices to prevent and treat painful neuromas.
- Country
- Netherlands
- Founded
- 2024
- Sector
- Medtech
- Funding stage
- Seed or earlier
- Founders
Why Atraxon Biotech stands out
Atraxon Biotech is addressing painful neuromas, disorganized and hypersensitive nerve regrowth that can form after trauma, surgery or amputation. Its patented biodegradable Y- and U-cassettes are designed to give regenerating axons a structured pathway rather than leaving the nerve end exposed to uncontrolled regrowth.
The Y-Cassette has moved into approved in-vivo validation. Co-founder Nancy Lamerigts also brings prior surgical-device experience from EIT, the 3D-printed spinal implant startup acquired by Johnson & Johnson in 2018.
What Atraxon Biotech is building
Atraxon Biotech is developing biodegradable cassettes for both established neuromas and freshly transected peripheral nerves. The devices guide regenerating axons into an autograft, tissue taken from the patient and used as a biological pathway for nerve regrowth.
The Y- and U-cassette formats are intended for different nerve sizes and anatomical locations. The surgical workflow is designed to avoid complex microsurgical reconstruction, giving the startup a product thesis centered on making nerve management more standardized and accessible to surgeons.
03
Oculum
Using AI virtual staining to make transparent eye tissue visible during surgery.
- Country
Canada- Founded
- 2024
- Sector
- Medtech
- Funding stage
- Seed or earlier
- Founders
Why Oculum stands out
Oculum is moving a visualization step in retinal surgery from chemical staining to software. Its second clinical study is underway at Sunnybrook, while the startup has received a $25,000 Tech@RBC Momentum Grant through the University of Toronto's Health Innovation Hub and has been selected for UTEST.
Founder Olga Klushina entered the problem through a Sunnybrook Medventions Innovation Fellowship and combines that clinical exposure with prior medical-imaging and systems-engineering experience.
What Oculum is building
Oculum is developing a modular microscope add-on that uses AI-powered virtual staining, computationally created contrast that highlights transparent tissue without applying a physical dye. The software works from the live surgical microscope feed and is designed to make retinal tissue visible during membrane peeling.
By integrating with microscopes already installed in eye operating rooms, Oculum is targeting an existing visualization step rather than asking hospitals to replace a major capital asset. Guidance remains inside the live microscope view while the procedure is underway.
Developing robotic systems for AI-assisted bone surgery.
- Country
France- Founded
- 2023
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why Surgitec Robotics stands out
Surgitec Robotics has raised more than €8 million and filed a patent application covering contactless robot-to-patient alignment using medical imaging. Two founders bring direct experience from the ROSA surgical-robotics platform: Michel Lefranc co-developed ROSA and led CHU Amiens-Picardie through its 100th robot-assisted spine procedure, while Florian Coiseur spent nearly eight years at the startup that built ROSA.
That background connects the startup's commercial thesis to prior deployment experience in surgical robotics, technology that uses robotic systems to guide or execute parts of an operation with controlled positioning.
What Surgitec Robotics is building
Surge One is a shared robotic platform for hard-tissue procedures across neurosurgery, spine, orthopedics, maxillofacial surgery and ENT. The system is designed around one hospital installation rather than a separate robot for each specialty.
For patient alignment, Surge One projects a laser line onto the operating area and matches its shape with the patient's medical imaging. This registration step, the process of matching the robot's coordinate system to the patient's anatomy, is designed to work without attaching a physical marker to the bone.
Developing a vascular device to block blood flow while preserving catheter access.
- Country
Ireland- Founded
- 2024
- Sector
- Medtech
- Funding stage
- Seed or earlier
Why LaNua Medical stands out
LaNua Medical pairs an unusual procedural design with a founding team experienced in vascular devices, interventional radiology and medical-device commercialization. CEO Tom Fitzmaurice spent 20 years at Medtronic, including 11 years leading operations for its coronary vascular business.
The startup raised a €6 million seed round co-led by Elkstone and Atlantic Bridge, with Enterprise Ireland and Furthr VC participating. Its ECORE program also secured €6 million in Disruptive Technologies Innovation Fund project funding with University College Dublin and Integer Holdings.
What LaNua Medical is building
ECORE is an umbrella-shaped device for embolization, a minimally invasive procedure that intentionally blocks a blood vessel to control bleeding, reduce blood supply to a target or treat a vascular abnormality. The device is delivered through a catheter and creates a mechanical barrier at the selected vessel segment.
Its distinctive feature is a central channel that remains open after occlusion, allowing guidewires and catheters to pass through the device. That preserves access to vessels beyond the treated point for imaging or additional treatment, addressing a practical limitation of conventional embolization materials.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Investment perspective
The investor pattern across these startups is procedural integration. The strongest products do not ask a surgical team to rebuild the entire workflow. They insert a new layer into a step that already exists: visualizing anatomy, managing a transected nerve, distinguishing transparent tissue, registering a robot to the patient or occluding a vessel.
That makes workflow evidence unusually important. In surgical technology, a technically impressive device still has to justify operating-room time, training burden, capital cost and compatibility with existing equipment. Early signals such as repeated clinical use, time savings, in-vivo validation, integration with installed microscopes and preservation of downstream catheter access speak directly to those adoption questions.
The group also shows where defensibility can come from beyond a single patent. Clinical workflow knowledge, surgeon-founder experience, existing hospital infrastructure and the ability to work across multiple procedures can all widen the commercial value of the core technology. For investors, the next milestones are likely to be the ones that show the product can move from a technically credible intervention to a repeatable part of routine care.
Methodology
DealBio selected these five early-stage surgical technology startups because each changes a defined step inside an invasive procedure. The selection spans surgical visualization, peripheral-nerve management, retinal imaging, robotic hard-tissue surgery and endovascular embolization, with an emphasis on technologies that alter how clinicians see, navigate, manipulate tissue or preserve access during treatment.
DealBio builds its Startup Briefs using publicly available startup materials, ecosystem sources, market references and professional profiles.